ABBV - AbbVie Inc Stock Price, Fair Value and News

164.59USD+0.34 (+0.21%)Market Closed

Market Summary

USD164.59+0.34

Market Closed

0.21%

ABBV Alerts

2 major insider sales recently.

ABBV Stock Price

View Fullscreen

ABBV RSI Chart

ABBV Valuation

Market Cap

290.7B

Price/Earnings (Trailing)

59.79

Price/Sales (Trailing)

5.35

EV/EBITDA

34.86

Price/Free Cashflow

13.18

ABBV Price/Sales (Trailing)

ABBV Profitability

EBT Margin

11.51%

Return on Equity

46.94%

Return on Assets

3.61%

Free Cashflow Yield

7.59%

ABBV Fundamentals

ABBV Revenue

Revenue (TTM)

54.3B

Rev. Growth (Yr)

-5.42%

Rev. Growth (Qtr)

2.69%

ABBV Earnings

Earnings (TTM)

4.9B

Earnings Growth (Yr)

-66.76%

Earnings Growth (Qtr)

-53.77%

Breaking Down ABBV Revenue

Last 7 days

-1.8%

Last 30 days

-8.4%

Last 90 days

-0.1%

Trailing 12 Months

2.1%

How does ABBV drawdown profile look like?

ABBV Financial Health

Current Ratio

0.87

Debt/Equity

5.04

Debt/Cashflow

0.44

ABBV Investor Care

Dividend Yield

1.5%

Dividend/Share (TTM)

2.63

Buy Backs (1Y)

0.17%

Diluted EPS (TTM)

2.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	56.7B	56.0B	55.1B	54.3B
2022	56.7B	57.3B	57.8B	58.1B
2021	50.2B	53.7B	55.2B	56.2B
2020	34.1B	36.2B	40.6B	45.8B
2019	32.6B	32.6B	32.9B	33.3B
2018	29.6B	30.9B	32.2B	32.8B
2017	26.2B	26.7B	27.3B	28.2B
2016	23.8B	24.8B	25.2B	25.6B
2015	20.4B	21.0B	21.9B	22.9B
2014	19.0B	19.3B	19.6B	20.0B
2013	18.5B	18.7B	18.9B	18.8B
2012	17.7B	17.9B	18.1B	18.4B
2011	0	0	0	17.4B
2010	0	0	0	15.6B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AbbVie Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 20, 2024	donoghoe nicholas	sold	-3,716,760	176	-21,082	evp, chief bus/strat officer
Mar 18, 2024	stewart jeffrey ryan	acquired	1,602,110	61.36	26,110	evp, chief commercial officer
Mar 18, 2024	stewart jeffrey ryan	sold	-10,539,500	178	-58,949	evp, chief commercial officer
Mar 01, 2024	richmond timothy j.	acquired	2,804,150	61.36	45,700	evp, chief hr officer
Mar 01, 2024	richmond timothy j.	sold	-13,415,500	177	-75,680	evp, chief hr officer
Feb 29, 2024	buckbee kevin k	sold	-908,688	176	-5,144	svp, controller
Feb 29, 2024	siatis perry c	sold	-1,754,550	177	-9,891	evp, gc and secretary
Feb 29, 2024	michael robert a.	acquired	1,257,010	58.303	21,560	pres & chief operating officer
Feb 29, 2024	michael robert a.	sold	-12,154,000	176	-68,879	pres & chief operating officer
Feb 28, 2024	gonzalez richard a	sold (taxes)	-19,733,500	178	-110,249	chairman of the board and ceo

Which funds bought or sold ABBV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	JEPPSON WEALTH MANAGEMENT, LLC	reduced	-2.84	221,994	1,788,480	0.69%
Apr 17, 2024	Patten Group, Inc.	reduced	-4.52	34,254	315,215	0.08%
Apr 17, 2024	Stanley-Laman Group, Ltd.	unchanged	-	56,159	376,947	0.05%
Apr 17, 2024	PEOPLES FINANCIAL SERVICES CORP.	reduced	-3.99	526,143	4,629,880	2.01%
Apr 17, 2024	Acropolis Investment Management, LLC	reduced	-0.04	150,626	1,013,100	0.07%
Apr 17, 2024	Alpha Omega Wealth Management LLC	reduced	-3.36	1,258,290	10,537,400	1.96%
Apr 17, 2024	Town & Country Bank & Trust CO dba First Bankers Trust CO	added	0.07	644,612	4,309,030	1.84%
Apr 17, 2024	Gradient Capital Advisors, LLC	added	2.24	40,273	240,692	0.09%
Apr 17, 2024	Private Ocean, LLC	added	2.04	83,239	501,503	0.05%
Apr 17, 2024	Cornerstone Wealth Group, LLC	added	128	7,557,950	12,032,000	1.11%

Are Funds Buying or Selling ABBV?

Are funds buying ABBV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABBV

No. of Funds

ABBV Alerts

2 major insider sales recently.

Unveiling AbbVie Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.08%	160,380,057	SC 13G/A
Jan 25, 2024	blackrock inc.	8.1%	143,180,060	SC 13G/A
Feb 16, 2023	blackrock inc.	7.8%	138,702,758	SC 13G/A
Feb 09, 2023	vanguard group inc	8.95%	158,317,552	SC 13G/A
Feb 09, 2022	vanguard group inc	8.28%	146,312,069	SC 13G/A
Feb 03, 2022	blackrock inc.	7.3%	128,197,555	SC 13G/A
Feb 16, 2021	capital research global investors	2.1%	37,921,062	SC 13G/A
Feb 10, 2021	vanguard group inc	8.08%	142,563,074	SC 13G/A
Jan 29, 2021	blackrock inc.	7.0%	124,423,484	SC 13G/A
Feb 14, 2020	capital research global investors	5.8%	86,602,693	SC 13G/A

Recent SEC filings of AbbVie Inc

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	PX14A6G	PX14A6G
Mar 26, 2024	PX14A6G	PX14A6G
Mar 22, 2024	4	Insider Trading
Mar 21, 2024	144/A	144/A
Mar 20, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to AbbVie Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	351.1B	85.2B	-6.70%	-10.33%	9.99	4.12	6.46%	95.94%
MRK	317.1B	60.1B	2.45%	9.70%	868.73	5.27	1.40%	-97.49%
PFE	143.3B	46.5B	-8.14%	-36.93%	-103.22	3.08	42.59%	-114.62%
AMGN	140.8B	28.2B	-3.32%	6.70%	20.96	4.99	7.09%	2.52%
GILD	82.4B	27.1B	-9.93%	-21.39%	14.54	3.04	-0.60%	23.36%
TEVA	14.3B	15.8B	-4.27%	50.53%	-24.85	0.9	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-0.96%	-17.31%	-319.58	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-14.12%	-18.81%	11.17	2.39	49.61%	324.78%
BHC	3.1B	8.8B	-9.85%	14.21%	-5.31	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-13.30%	-10.60%	13.51	2.88	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-9.90%	-28.22%	-3.8	1.8	24.65%	80.36%
TXMD	21.7M	1.3M	-17.90%	-49.05%	-2.11	16.65	-98.14%	-109.18%
ACRX	17.6M	-	-9.57%	32.48%	-0.96	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-30.19%	-94.45%	-0.18	0.13	80.00%	43.08%
ACOR	422.3K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

AbbVie Inc News

Latest updates

AbbVie Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	2.7%	14,301	13,927	13,865	12,225	15,121	14,812	14,583	13,538	14,886	14,342	13,959	13,010	13,858	12,902	10,425	8,619	8,704	8,479	8,255	7,828	8,305
Costs and Expenses	-4.6%	11,106	11,646	9,352	9,457	9,619	10,209	11,288	8,821	9,812	10,036	9,518	8,907	10,105	9,647	9,673	5,016	4,748	5,862	4,855	4,818	10,746
S&GA Expenses	-5.3%	3,193	3,372	3,268	3,039	3,417	3,304	5,412	3,127	3,260	3,083	3,164	2,842	3,231	2,846	3,527	1,695	1,951	1,657	1,654	1,680	1,929
EBITDA Margin	-	0.17*	-	0.25*	0.22*	0.29*	0.32*	0.31*	0.31*	0.29*	0.19*	0.18*	0.15*	0.15*	-	-	-	-	-	-	-	-
Income Taxes	125.6%	388	172	583	234	493	448	255	436	226	508	394	312	-1,545	187	46.00	88.00	273	117	66.00	88.00	-547
Earnings Before Taxes	-37.9%	1,212	1,953	2,610	475	2,965	4,400	1,183	4,929	4,271	3,688	1,163	3,867	-1,507	2,500	-693	3,098	3,074	2,001	807	2,544	-2,373
EBT Margin	-20.7%	0.12*	0.15*	0.19*	0.16*	0.23*	0.26*	0.25*	0.25*	0.23*	0.13*	0.11*	0.08*	-	-	-	-	-	-	-	-	-
Net Income	-53.8%	822	1,778	2,024	239	2,473	3,949	924	4,490	4,044	3,179	766	3,553	36.00	2,308	-738	3,010	2,801	1,884	741	2,456	-1,826
Net Income Margin	-24.2%	0.09*	0.12*	0.16*	0.13*	0.20*	0.23*	0.22*	0.22*	0.21*	0.14*	0.12*	0.10*	-	-	-	-	-	-	-	-	-
Free Cashflow	-38.2%	4,548	7,355	6,141	4,018	7,215	7,425	4,862	4,746	4,888	7,718	4,695	4,689	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.1%	134,711	136,221	135,367	134,544	138,805	141,325	143,186	143,211	146,529	148,858	147,972	150,501	150,565	149,621	149,530	91,199	89,115	59,441	57,142	56,769	59,352
Current Assets	-0.7%	33,002	33,224	28,852	26,488	28,463	30,364	29,100	26,509	27,928	28,957	25,999	26,569	24,173	23,009	21,256	51,758	49,519	20,166	15,100	14,413	16,945
Cash Equivalents	-3.6%	12,814	13,287	8,759	6,711	9,201	11,832	8,521	6,098	9,746	12,182	8,546	9,755	8,449	7,890	6,017	41,142	39,924	10,648	5,172	4,897	7,289
Inventory	3.0%	4,099	3,981	4,055	3,833	3,579	3,172	3,396	3,483	3,128	3,094	3,386	3,272	3,310	3,474	4,059	1,844	1,813	1,929	1,895	1,702	1,605
Net PPE	1.1%	4,989	4,934	4,943	4,931	4,935	4,893	4,958	5,075	5,110	5,130	5,161	5,193	5,248	4,986	4,908	2,961	2,962	2,894	2,879	2,860	2,883
Goodwill	0.6%	32,293	32,091	32,224	32,220	32,156	31,726	32,028	32,298	32,379	32,296	32,398	32,349	33,124	42,801	42,669	15,561	15,604	15,537	15,642	15,606	15,663
Current Liabilities	8.8%	37,841	34,773	32,239	27,590	29,538	32,712	34,473	32,521	35,194	28,533	28,684	31,951	28,661	24,181	24,646	16,471	15,585	17,493	16,941	13,904	17,239
Short Term Borrowings	-100.0%	-	2.00	-	1.00	1.00	10.00	17.00	12.00	14.00	16.00	17.00	9.00	34.00	54.00	64.00	6.00	-	-	306	499	3,699
Long Term Debt	-6.2%	52,194	55,631	55,812	59,292	59,135	60,399	61,002	63,522	64,189	74,049	74,237	74,183	77,554	82,282	82,061	63,284	62,975	33,126	31,619	35,066	35,002
Shareholder's Equity	-14.3%	10,360	12,094	12,898	13,303	17,254	16,027	14,688	16,314	15,436	13,577	12,594	13,733	13,097	15,289	14,732	-	-	-	-	-	-
Retained Earnings	-207.2%	-1,000	933	1,789	2,393	4,784	4,953	3,516	5,103	3,127	1,600	740	2,292	1,055	3,335	3,130	5,973	4,717	3,673	3,384	4,234	3,368
Additional Paid-In Capital	0.8%	20,180	20,021	19,839	19,619	19,245	19,056	18,906	18,731	18,305	18,108	17,936	17,712	17,384	17,148	16,953	15,401	15,193	15,112	15,028	14,940	14,756
Shares Outstanding	0%	1,768	1,768	1,768	1,770	1,771	1,771	1,770	1,771	1,770	1,769	1,769	1,769	-	-	-	-	-	-	-	-	-
Minority Interest	5.7%	37.00	35.00	32.00	29.00	33.00	33.00	35.00	31.00	28.00	27.00	25.00	23.00	21.00	19.00	24.00	-	-	-	-	-	-
Float	-	-	-	235,630	-	-	-	268,253	-	-	-	197,246	-	-	-	171,597	-	-	-	106,362	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-37.2%	4,753	7,574	6,319	4,193	7,428	7,602	5,005	4,908	5,075	7,935	4,890	4,877	4,854	5,830	3,089	3,815	3,275	4,555	2,477	3,017	3,392
Share Based Compensation	-3.8%	125	130	179	313	132	126	107	306	129	135	159	269	136	162	236	219	79.00	75.00	87.00	189	70.00
Cashflow From Investing	-116.8%	-800	-369	-341	-499	-448	1,286	130	-1,591	-1,145	-615	-242	-342	-627	-1,149	-35,652	-129	-615	1,378	-140	-27.00	-283
Cashflow From Financing	-67.2%	-4,449	-2,661	-3,920	-6,192	-9,634	-5,518	-2,679	-6,972	-6,338	-3,643	-5,884	-3,174	-3,695	-2,814	-2,570	-2,422	26,602	-441	-2,070	-5,383	-3,825
Dividend Payments	0.0%	2,626	2,627	2,625	2,661	2,506	2,504	2,507	2,526	2,314	2,315	2,310	2,322	2,101	2,100	1,752	1,763	1,595	1,591	1,592	1,588	1,451
Buy Backs	-25.0%	3.00	4.00	10.00	1,955	4.00	4.00	9.00	1,470	131	6.00	10.00	787	296	20.00	19.00	643	2.00	4.00	3.00	620	2,058

ABBV Income Statement

2023-12-31

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenues	$ 54,318	$ 58,054	$ 56,197
Cost of products sold	20,415	17,414	17,446
Selling, general and administrative	12,872	15,260	12,349
Research and development	7,675	6,510	6,922
Acquired IPR&D and milestones	778	697	1,124
Other operating expense (income), net	(179)	56	432
Total operating costs and expenses	41,561	39,937	38,273
Operating earnings	12,757	18,117	17,924
Interest expense, net	1,684	2,044	2,384
Net foreign exchange loss	146	148	51
Other expense, net	4,677	2,448	2,500
Earnings before income tax expense	6,250	13,477	12,989
Income tax expense	1,377	1,632	1,440
Net earnings	4,873	11,845	11,549
Net earnings attributable to noncontrolling interest	10	9	7
Net earnings attributable to AbbVie Inc.	$ 4,863	$ 11,836	$ 11,542
Per share data
Basic earnings per share (in dollars per share)	$ 2.73	$ 6.65	$ 6.48
Diluted earnings per share (in dollars per share)	$ 2.72	$ 6.63	$ 6.45
Weighted-average basic shares outstanding (in shares)	1,768	1,771	1,770
Weighted-average diluted shares outstanding (in shares)	1,773	1,778	1,777

ABBV Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and equivalents	$ 12,814	$ 9,201
Short-term investments	2	28
Accounts receivable, net	11,155	11,254
Inventories	4,099	3,579
Prepaid expenses and other	4,932	4,401
Total current assets	33,002	28,463
Investments	304	241
Property and equipment, net	4,989	4,935
Intangible assets, net	55,610	67,439
Goodwill	32,293	32,156
Other assets	8,513	5,571
Total assets	134,711	138,805
Current liabilities
Short-term borrowings	0	1
Current portion of long-term debt and finance lease obligations	7,191	4,135
Accounts payable and accrued liabilities	30,650	25,402
Total current liabilities	37,841	29,538
Long-term debt and finance lease obligations	52,194	59,135
Deferred income taxes	1,952	2,190
Other long-term liabilities	32,327	30,655
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,823,046,087 shares issued as of December 31, 2023 and 1,813,770,294 as of December 31, 2022	18	18
Common stock held in treasury, at cost, 57,105,354 shares as of December 31, 2023 and 44,589,000 as of December 31, 2022	(6,533)	(4,594)
Additional paid-in capital	20,180	19,245
Retained earnings (accumulated deficit)	(1,000)	4,784
Accumulated other comprehensive loss	(2,305)	(2,199)
Total stockholders' equity	10,360	17,254
Noncontrolling interest	37	33
Total equity	10,397	17,287
Total liabilities and equity	$ 134,711	$ 138,805

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal BehÃƒÂ§et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

CEO	Mr. Richard A. Gonzalez
WEBSITE	abbvie.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	50000

AbbVie Inc Frequently Asked Questions

What is the ticker symbol for AbbVie Inc? What does ABBV stand for in stocks?

ABBV is the stock ticker symbol of AbbVie Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbbVie Inc (ABBV)?

As of Thu Apr 18 2024, market cap of AbbVie Inc is 290.74 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart for subscribers.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart for subscribers. The fair value of AbbVie Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbbVie Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABBV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbbVie Inc a good stock to buy?

The fair value guage provides a quick view whether ABBV is over valued or under valued. Whether AbbVie Inc is cheap or expensive depends on the assumptions which impact AbbVie Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABBV.

What is AbbVie Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, ABBV's PE ratio (Price to Earnings) is 59.79 and Price to Sales (PS) ratio is 5.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABBV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AbbVie Inc's stock?

In the past 10 years, AbbVie Inc has provided 0.168 (multiply by 100 for percentage) rate of return.